Browsing by Author Bosch Barrera, Joaquim

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)
24-Dec-2021Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor SilibininBosch Barrera, Joaquim; Roqué, Ariadna; Teixidor, Eduard; Carmona Garcia, Maria Carmen; Arbusà, Aina; Brunet, Joan; Martin Castillo, Begoña; Cuyàs, Elisabet; Verdura, Sara; Menendez, Javier A.
2-Sep-2013IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutationsVazquez Martin, Alejandro; Cufí, Sílvia; Oliveras Ferraros, Cristina; Torres Garcia, Violeta Zenobia; Corominas Faja, Bruna; Cuyàs, Elisabet; Bonavia, Rosa; Visa, Joana; Martin Castillo, Begoña; Barrajón Catalán, Enrique; Micol, Vicente; Bosch Barrera, Joaquim; Menendez, Javier A.
6-Nov-2018Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental ValidationCuyàs, Elisabet; Verdura, Sara; Llorach Parés, Laura; Fernández Arroyo, Salvador; Joven, Jorge; Martin Castillo, Begoña; Bosch Barrera, Joaquim; Brunet, Joan; Nonell Canals, Alfons; Sánchez Martínez, Melchor; Menendez, Javier A.
15-Jan-2020Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunityVerdura, Sara; Cuyàs, Elisabet; Cortada, Eric; Brunet, Joan; Lopez Bonet, Eugeni; Martin Castillo, Begoña; Bosch Barrera, Joaquim; Encinar, José Antonio; Menendez, Javier A.
4-Feb-2021SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)Nadal, Ernest; Bosch Barrera, Joaquim; Cedrés, S.; Coves, J.; García Campelo, R.; Guirado, M.; López Castro, R.; Ortega, A. L.; Vicente, D.; Castro Carpeño, J. de
1-Jun-2020Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 PatientsBosch Barrera, Joaquim; Martín Castillo, Begoña; Buxó, Maria; Brunet, Joan; Encinar, José Antonio; Menendez, Javier A.
21-Aug-2013Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivoCufí, Sílvia; Bonavia, Rosa; Vazquez Martin, Alejandro; Oliveras Ferraros, Cristina; Corominas Faja, Bruna; Cuyàs, Elisabet; Martin Castillo, Begoña; Barrajón Catalán, Enrique; Visa, Joana; Segura-Carretero, Antonio; Joven, Jorge; Bosch Barrera, Joaquim; Micol, Vicente; Menendez, Javier A.
19-Aug-2021Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung CancerBosch Barrera, Joaquim; Verdura, Sara; Ruffinelli, José Carlos; Carcereny, Enric; Sais, Elia; Cuyàs, Elisabet; Palmero, Ramón; Lopez Bonet, Eugeni; Hernández Martínez, Alejandro; Oliveras Serrat, Glòria; Buxó, Maria; Izquierdo, Angel; Morán, Teresa; Nadal, Ernest; Menendez, Javier A.
13-Dec-2016Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancerQueralt, Bernat; Cuyàs, Elisabet; Bosch Barrera, Joaquim; Massaguer i Vall-llovera, Anna; Llorens Duran, Rafael de; Martin Castillo, Begoña; Brunet, Joan; Salazar Soler, Ramón; Menendez, Javier A.
1-Jan-2020The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypesCuyàs, Elisabet; Gumuzio, Juan; Verdura, Sara; Brunet, Joan; Bosch Barrera, Joaquim; Martín Castillo, Begoña; Alarcón Cor, Tomás; Encinar, José Antonio; Martin, Ángel G.; Menendez, Javier A.